Thomas Fagan is EVP, Neurodegenerative Portfolio at Cognito Therapeutics, where he leads the strategic development and commercialization readiness of the company’s Alzheimer’s programs, including the Spectris™ therapeutic platform. With more than 25 years of experience across the pharmaceutical, medical device, and diagnostics industries, Mr. Fagan has built and led organizations responsible for bringing innovative technologies from clinical development to real-world adoption. His work has focused on building integrated care ecosystems, aligning cross-functional teams, and developing clinical-to-commercial pathways that expand treatment options for patients living with neurodegenerative disease. Prior to joining Cognito, Mr. Fagan served as Vice President, U.S. Alzheimer’s Disease Commercial, at Eisai Inc., where he led the U.S. commercial strategy for the company’s Alzheimer’s portfolio and helped guide the launch and market expansion of LEQEMBI® (lecanemab). Earlier in his career at Eli Lilly and Company, he held several leadership roles in Alzheimer’s disease programs, including Global Commercial Leader and Global Brand Development Leader, where he helped lead commercialization efforts for Amyvid® (florbetapir), the first FDA-approved PET imaging agent for detecting amyloid plaques associated with Alzheimer’s disease. Mr. Fagan began his career at Goldman Sachs and has also held leadership roles at Baxter International and Momentum Life Sciences. He earned his MBA from Stanford University and holds a Bachelor of Arts in Economics from DePauw University, where he graduated summa cum laude and was elected to Phi Beta Kappa.
